Hogan Lovells advises the investors in their Series G investment in Doctolib

Paris, 16 March 2022 – Hogan Lovells advised the investors in Doctolib's new Series G funding round, which, with its €5.8 billion valuation, has become the most valuable unicorn in the French Tech sector.

This new €500 million equity and debt round was led by the investment funds Eurazeo, BPIfrance, and General Atlantic.

Thanks to this Series G funding round, Doctolib intends to double its workforce in five years. The company will also continue its development by adding new features to its platform.

The Hogan Lovells core team was led by Paris Private Equity partner Matthieu Grollemund, with support across a global team including:


  • Theresa Mengler (Senior Associate, IPMT)


  • Tina Welter (Senior Associate, SOAR)


  • Giuseppe Aminzade (Counsel, Pharmaceuticals and Biotechnologies)
  • Maria Luce Piattelli (Counsel, IPMT)
  • Giulia Mariuz (Senior Associate, SOAR) 
  • Chiara Perolari (Associate, Pharmaceuticals and Biotechnologies)
  • Eleonora Beltrame (Trainee)
  • Luisa Pomello Chinaglia (Trainee)Elia Salardi (Trainee)


  • Martin Pflueger (Partner, IPMT)
  • Joerg Schickert (Partner, SOAR)
  • Felicitas Rudolph (Senior Projects Associate, SOAR) 


  • Hélène Parent (Partner, Private Equity)
  • Eric Paroche (Partner, Competition)
  • Patrice Navarro (Partner, IP, IT and Regulatory & Medical)
  • Mikael Salmela (Partner, IP, IT and Regulatory & Medical)
  • Pierre-Marie Boya (Counsel, Private Equity)
  • Julie Schwartz (Senior Associate, IP, IT and Regulatory & Medical)
  • Céline Verney (Senior Associate, Competition) 
  • Madalina Asandului (Associate, Private Equity) 
  • Arthur Deschamps (Associate, Private Equity) 
  • Olga Kurochkina (Associate, IP, IT and Regulatory & Medical)
  • Joséphine Pour (Associate, IP, IT and Regulatory & Medical)
  • Gautier Valdiguié (Associate, Private Equity)


  • Massimiliano Masnada (Partner, SOAR) 

Click here to read the French version


Back To Listing